Brief: Krystal Biotech Announces Pipeline Expansion Into Oncology And FDA Acceptance Of Ind Application For Lead Oncology Candidate KB707
26/07/2023 22:39
July 26 (Reuters) - Krystal Biotech Inc KRYS.O :
* KRYSTAL BIOTECH ANNOUNCES PIPELINE EXPANSION INTO ONCOLOGY
AND
FDA ACCEPTANCE OF IND APPLICATION FOR LEAD ONCOLOGY CANDIDATE
KB707
* KRYSTAL BIOTECH INC - EXPECTS TO INITIATE A PHASE 1 STUDY
IN
SECOND HALF OF 2023
* KRYSTAL BIOTECH - PLANNING TO FILE AMENDMENT TO KB707 IND
IN
SECOND HALF OF 2023 TO EVALUATE INHALED KB707 IN A CLINICAL
TRIAL IN FIRST HALF OF 2024
Source text for Eikon: ID:nGNX3JYrxt
Further company coverage: KRYS.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion